SMN2 and proximal spinal muscular atrophy: In a group of SMA children who were treated with nusinersen before the age of three years, patients with two SMN2 gene copies demonstrated worse motor, respiratory, and orthopedic characteristics than those with three SMN2 gene copies after 36 months of therapy [11].